Tabelecleucel

Summary

Tabelecleucel (CHEMBL3990008) is an approved cell (ATC L01XL09); indicated across 4 conditions including lymphoproliferative syndrome and epstein-barr virus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Cell
• ATC class: L01XL09
• Indications: 4 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990008
Name	Tabelecleucel
Type	Cell
Max phase	4
ATC	L01XL09

Also known as: ATA-129, ATA129, EBV-CTL, Ebvallo, Tabelecleucel, TABELECLEUCEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lymphoproliferative syndrome	4	MONDO:0016537	Orphanet:2442
Epstein-Barr virus infection	4	MONDO:0005111	EFO:0000769
lymphoma	2	MONDO:0005062	EFO:0000574

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03394365	PHASE3	RECRUITING	A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT04554914	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
NCT03769467	PHASE1/PHASE2	TERMINATED	Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
NCT02822495	Not specified	NO_LONGER_AVAILABLE	Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).